Subjects not receiving antidiabetes therapy for @ weeks were randomized to empagliflozin @ mg/linagliptin @ mg ( n = @ ) , empagliflozin @ mg/linagliptin @ mg ( n = @ ) , empagliflozin @ mg ( n = @ ) , empagliflozin @ mg ( n = @ ) , or linagliptin @ mg ( n = @ ) for @ weeks .